フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Number of shares and votes in Calliditas Therapeutics PR Newswire STOCKHOLM, Dec. 30, 2022 STOCKHOLM, Dec. 30, 2022 /PRNewswire/ -- During...
Calliditas CEO acquires shares through the exercise of Calliditas' warrant program 2019/2022 PR Newswire STOCKHOLM, Dec. 21, 2022 STOCKHOLM, Dec...
Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan PR...
Calliditas to host fireside chat with its China commercial partner, Everest Medicines PR Newswire STOCKHOLM, Dec. 9, 2022 STOCKHOLM, Dec. 9, 2022...
Calliditas' partner Everest Medicine's New Drug Application for Nefecon is accepted by the China NMPA PR Newswire STOCKHOLM, Nov. 15, 2022...
Calliditas Therapeutics: Interim Report Q3, 2022 PR Newswire STOCKHOLM, Nov. 14, 2022 Conditional Marketing Authorization in EU Granted for...
Key Opinion Leader Fireside Chat with Professor Richard Lafayette on the US IgAN Treatment Landscape PR Newswire STOCKHOLM, Nov. 7, 2022...
Calliditas Therapeutics' nomination committee composition for the AGM 2023 PR Newswire STOCKHOLM, Oct. 21, 2022 Calliditas Therapeutics AB...
Kidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO® (budesonide) in IgA Nephropathy PR Newswire STOCKHOLM...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約